Former US President Jimmy Carter, who was diagnosed with melanoma that spread to his brain in 2015, has survived for nine ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a ...

周一，BMO Capital Markets维持了对临床阶段肿瘤公司Merus N.V. (NASDAQ:MRUS)的乐观立场，重申了"优于大市"评级和95.00美元的目标价。这一背书紧随Merus宣布开始在一项关键的3期试验（名为LiGeR-HN1）中给第一位患者用药。该研究正在评估petosemtamab（也称为peto）与pembrolizumab联合用于治疗此前未经治疗的头颈部癌症患者的疗 ...

The retrospective study presented at ESMO 2024 involved about 2,400 patients with stage 3 or 4 non-small cell lung cancer.

The 5-year OS rate for pembrolizumab vs placebo was 86.1% vs 81.7% with HR 0.51 (significant). 2. Immune-mediated adverse ...

PD-1 inhibitors have revolutionised cancer treatment over the last decade, with their success attributed to Keytruda and ...

荷兰乌特勒支 - 临床阶段肿瘤公司Merus N.V. (NASDAQ:MRUS)宣布启动一项3期临床试验，研究新型癌症治疗药物petosemtamab与pembrolizumab联合用于复发或转移性头颈部鳞状细胞癌(r/m HNSCC)患者的治疗。LiGeR-HN1试验已完成首例患者给药，该试验将比较这种联合疗法与单独使用pembrolizumab作为一线治疗的疗效和安全性。 Petosemta ...

After hours of company pushback, FDA's Oncologic Drugs Advisory Committee voted that the benefit of immunotherapy in low or ...

Key data readouts for the company’s late-stage, potentially registrational trials of nemvaleukin are expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal ...

Just four years earlier, the Food and Drug Administration had approved the first so-called checkpoint inhibitor, generically ...

Sep. 27, 2024 — Estrogens are known to drive tumor growth in breast cancer cells that carry its receptors, but a new study unexpectedly finds that estrogens play a role in fueling the growth of ...

Dr. Gopakumar Iyer discussed how to Integrate Novel Therapeutics with trimodal therapy (TMT). Radiation therapy (RT) has ...